InduPro Raises $77M Series B Led by The Column Group and Doses First Patient in Phase 1 Trial of IDP-001

InduPro closed a $77 million Series B financing led by The Column Group and dosed the first patient in a Phase 1 trial of IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumor-associated proximity antigen for advanced squamous NSCLC and other solid tumors.